

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial.

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/84541> since

Published version:

DOI:10.1001/jama.2010.1796

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

[JAMA,304(23),2010, doi: 10.1001/jama.2010.1796]

The definitive version is available at:

La versione definitiva è disponibile alla URL:

[http://jama.jamanetwork.com/data/Journals/JAMA/4541/jpc05010_2620_2627.pdf]

EFFECT OF A LUNG PROTECTIVE STRATEGY IN ORGAN DONORS ON ELIGIBILITY AND AVAILABILITY OF LUNGS FOR TRANSPLANTATION: A RANDOMIZED CLINICAL TRIAL¹

Clinicaltrials.gov identifier: NCT00260676

LUCIANA MASCIA, MD, PhD², DANIELA PASERO, MD², ARTHUR S. SLUTSKY, MD³, M. JOSE ARGUIS, MD⁴, MAURIZIO BERARDINO, MD⁵, SALVATORE GRASSO, MD⁶, MARINA MUNARI, MD⁷, SILVIA BOIFAVA, MD⁸, GIUSEPPE CORNARA, MD⁹, FRANCESCO DELLA CORTE, MD¹⁰, NICOLETTA VIVALDI, MD¹¹, PAOLO MALACARNE, MD¹², PAOLO DEL GAUDIO, MD¹³, SERGIO LIVIGNI, MD¹⁴, ELISABETH ZAVALA, MD⁴, CLAUDIA FILIPPINI, PhD², ERICA L. MARTIN, PhD², PIER PAOLO DONADIO, MD², ILARIA MASTROMAURO, MD², AND V. MARCO RANIERI, MD²

Address for correspondence:

V. Marco Ranieri, MD
Università di Torino, Dipartimento di Anestesia
Azienda Ospedaliera S. Giovanni Battista-Molinette
Corso Dogliotti 14, 10126 Torino
Tel: 39-011-633-4001; Fax: 39-011-696-0448
e-mail: marco.ranieri@unito.it

- 1) Supported by grants from Ministero della Salute, Programma Ricerca Finalizzata # VMR23a/2004-2006, Regione Piemonte, Programma Ricerca Finalizzata # CIPE LM002/2005-2007, Ministero dell'Università, Programmi di Ricerca di Interesse Nazionale # VMRLM98, 2007-2009
- 2) Terapia Intensiva Generale, Ospedale S. Giovanni Battista-Molinette Università di Torino, Italy
- 3) Keenan Research Center at the Li Ka Shing Institute of St. Michael's Hospital; Department of Medicine and Interdepartmental Division of Critical Care Medicine, University of Toronto; King Saud University; Visiting Professor, Università di Torino, Italy
- 4) Anesthesia and Intensive Care Medicine, Hospital Clinic, University of Barcelona, Spain
- 5) Neuro-rianimazione, Ospedale S. Giovanni Battista-Molinette, Università di Torino, Italy
- 6) Anestesia e Rianimazione, Ospedale Consorziale Policlinico, Università di Bari, Italy
- 7) Anestesia e Rianimazione, Azienda Ospedaliera di Padova, Università di Padova Italy
- 8) Anestesia e Rianimazione, Azienda Ospedaliera CTO, Torino, Italy
- 9) Anestesia e Rianimazione, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy
- 10) Anestesia e Rianimazione, Ospedale Maggiore della Carità, Università di Novara, Italy
- 11) Anestesia e Rianimazione, Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
- 12) Anestesia e Rianimazione, Ospedale Santa Chiara, Pisa, Italy
- 13) Rianimazione DEA, Ospedale S. Giovanni Battista-Molinette, Università di Torino, Italy
- 14) Anestesia e Rianimazione, Ospedale Giovanni Bosco, Torino, Italy

ABSTRACT

Context: Many potential donor lungs deteriorate between the time of brain death and evaluation for transplantation suitability, possibly because of the ventilatory strategy used after brain death.

Objective: To test whether a lung protective strategy increases the number of lungs available for transplantation.

Design, setting and patients: Multicenter, randomized trial of patients with beating hearts who were potential organ donors conducted at 12 European Intensive care units from September 2004 to May 2009 in the protective Ventilatory Strategy in Potential Lung Donors Study.

Interventions: Potential donors were randomized to the conventional ventilatory strategy (with tidal volumes 10-12 mL/Kg of predicted body weight, positive end-expiratory pressure [PEEP] of 3-5 cmH₂O; apnea tests performed by disconnecting the ventilator, and closed circuit for airway suction) or the protective ventilatory strategy (with tidal volumes 6-8 mL/Kg of predicted body weight, PEEP, OF 8-10 cmH₂O, apnea tests performed by using positive airway pressure, and closed circuit for airway suction).

Main outcome measures: The number of organ donors meeting eligibility criteria for harvesting; number of lungs harvested, and 6-month survival of lung transplant recipients.

Results: The trial was stopped after enrolling 118 patients (59 in conventional ventilatory strategy and 59 in the protective ventilatory strategy) because of termination of funding. The number of patients who met lung donor eligibility criteria after the 6-hour observation period was 32 (54%) in the conventional strategy vs. 56 (95%) in the protective strategy (difference 41% [95% confidence interval {CI}, 26.5% to 54.8%]; $P < 0.001$). The number of patients in whom lungs were harvested was 16 (27%) in the conventional strategy vs. 32 (54%) in the protective strategy (difference of 27% [95% CI, 10.0% to 44.5%]; $P = 0.004$). Six-month survival rates did not differ between recipients who received lungs from donors ventilated with conventional strategy compared with the protective strategy 11/16 [69%] vs 24/32 [75%], respectively; difference of 6% [95% CI, -22% to 32%]).

Conclusions: Use of a lung protective strategy in potential organ donors with brain-death increased the number of eligible and harvested lungs compared to a conventional strategy.

Key words: lung protective strategy, organ donors, brain death

INTRODUCTION

There is evidence in various settings demonstrating that a lung protective strategy is beneficial. In patients with acute lung injury ventilation with low tidal volumes decreased absolute mortality by 9%⁷. In patients with normal pulmonary function, ventilation with lower tidal volumes was associated with a lower likelihood of developing acute lung injury⁸. In patients with brain injuries, ventilation with higher tidal volumes was an independent factor contributing to development of acute lung injury(6).

Despite this evidence, there is controversy as to the best ventilatory strategy to use in patients diagnosed as having brain death. A consensus conference(9) recommended ventilation with low tidal volumes of 10 to 12 ml/kg of measured body weight and positive end-expiratory pressure (PEEP) of 5 cmH₂O⁹. A subsequent review article¹⁰ and an observational study¹¹ suggested that potential donors should receive ventilated with low tidal volumes of 8 to 10 ml/kg of predicted body weight . Guidelines for potential organ donors currently recommend ventilation with higher levels of low tidal volume (10-15 mL/kg of measured body weight)^{12 13}.

We hypothesized that a protective lung strategy in patients diagnosed as having brain death would decrease the development of lung dysfunction and increase the number of lungs available for transplantation.

METHODS

Potential donors were from 12 intensive care units in Italy and Spain, had normal heart beat patterns, and had been reported to organ procurement organizations between September 2004 and May 2009. The Ethics review boards of all hospitals approved the protocol and relatives of the patients provided consent for organ donation. Exclusion criteria were denied consent for organ donation; legal issues preventing organ donation; history of cardiac arrest; age younger than 18 years old or older than 65 years; radiographic pulmonary infiltrates; duration of mechanical ventilation until brain death longer than 5 days; smoking history (>20 pack years), asthma or chronic obstructive pulmonary disease, chest trauma or previous thoracic surgery and aspiration pneumonia or purulent secretions diagnosed by bronchoscopy, sputum, or bronchoalveolar lavage positive for Gram stain, fungus or white blood cells^{3, 14, 15}.

The Protective Ventilatory Strategy in Potential Lung Donors Study used a central Web site that created a concealed, computer-generated block randomization schedule that assigned patients to either the “*conventional*” or “*protective*” lung ventilatory strategy, which was applied during the observation period required for declaration of brain death (6 hours), and maintained until patients arrived in the operating department for organ extraction.

In the conventional strategy, patients received ventilation with low tidal volumes of 10 to 12 mL/kg of predicted body weight⁷ and PEEP of 3 to 5 cmH₂O². An open circuit was used

for tracheal suction. Apnea tests were performed by disconnecting the patient from the ventilator, while administering high-flow oxygen.

In the protective strategy patients received ventilation with low tidal volumes of 6 to 8 mL/kg of predicted body weight and PEEP of 8 to 10 cmH₂O. A closed circuit was used for tracheal suction¹⁶. Apnea tests were performed with the ventilator in the continuous positive airway pressure mode¹⁷. Continuous positive airway pressure was set equal to the previous PEEP used during mechanical ventilation. Recruitment maneuvers (doubling ventilation with low tidal volumes for 10 breaths)¹⁸ were performed after any disconnection from the ventilator.

In both strategy groups, respiratory rate was adjusted to obtain PaCO₂ of 40 to 45 mmHg and fraction of inspired oxygen (FiO₂) was adjusted to obtain PaO₂ of 90 mmHg or greater. The viability of lungs was assessed at the beginning and at the end of the 6-hour observation period^{3,14}. The ratio of PaCO₂ to FiO₂ and of peak airway pressure at the end of the 6-hour observation period were reported to the organ procurement organization^{3,14}. The officer of the organ procurement organization was not aware of patient allocation and was not involved in the study. The officer of the organ procurement organization declared the potential donor as eligible for harvesting of the lungs when the ratio of PaO₂ to FiO₂ was 300 mmHg or greater, FiO₂ was 1.0, and peak airway pressure was less than 30 cmH₂O^{3,14}. The officer of the organ procurement organization then reported the potential lung donor to

the lung transplant surgeon who, after examining the potential donor, made the final decision on the suitability of the lungs. The surgeon was blinded to patient allocation and was not otherwise involved in the study. The reasons given by the lung transplant surgeon not to harvest lungs were prospectively classified as (1) lung donor issues (functional lungs that at the moment of harvest no longer met oxygenation and peak airway pressure criteria for eligibility; infectious, clinical, radiological, or laboratory manifestation of pulmonary infection occurring after diagnosis of brain death; or laboratory manifestation of pulmonary contusions observed during inspection of the lungs with the chest open) and (2) lung recipient issues (donor-recipient incompatibility, lack of potential recipients matching size, blood group or human leukocyte antigen compatibility, or logistical [inability of the surgical team to proceed in time for harvest, collection, and transplantation]). The number of harvested hearts, livers and kidneys in both groups was recorded.

The primary outcome of the study was the number of potential donors meeting eligibility criteria for lung harvest at the end of the 6-hour observation period. Other clinical outcomes were the number of lungs harvested and number of patients who received lung transplants who were alive at 6 months.

Six-month survival also was recorded for patients who received other organs harvested from the donors. Duration of intensive care units stay was recorded in lung transplant recipients.

Blood samples were collected at the beginning and end of the 6-hour observation period for measurements of IL-1 β , IL-1 receptor antagonist, IL-6, IL-8, tumor necrosis factor and tumor necrosis factor receptors I and II⁵.

In a previous observational study², we found that 54% of potential lung donors met eligibility criteria for lung donation. Based on this, the study was powered for 200 patients to demonstrate a 25% absolute increase in eligible lungs (from 50% to 75%), with a 5% risk of type I error, and power level of 90%. An interim analysis was planned after data were obtained on the first 100 patients. The stopping boundaries of the study were based on the primary end point and were designed to allow termination of the study if the protective strategy was better than conventional (control) strategy ($P < 0.003$), or for futility ($P > 0.03$)¹⁹.

All analyses were conducted on an intention-to-treat basis. Data are presented as mean (SD), or median (inter-quartile range [IQR]). Comparisons between groups and within groups were made using the t test, the Wilcoxon rank sum test, the χ^2 test, the Fisher exact test and McNemar tests. All tests were 2-tailed. The primary outcome was evaluated using a multivariate logistic regression analysis. To examine the temporal effect across groups during the 6-hour observation period, relevant clinical variables were analyzed using a mixed-linear regression model for repeated measures in which each parameter was the dependent variables, while time and group were the independent variables. The number needed to treat to benefit also was estimated (ie, the number of patients with brain death

who had to be treated with the protective strategy to obtain an extra lung donor that met acceptability criteria). Results are reported as odds ratios (ORs) with 95% confidence intervals (95% CIs). To account for individual hospital effects, the cumulative OR was used as a measure of effect size in a robust logistical regression model. The level of statistical significance was set at 0.05. Statistical analysis was conducted using SAS software version 9.2 (SAS Institute Inc, Cary, North Carolina).

RESULTS

The Steering Committee stopped the Protective Ventilatory Strategy in Potential Lung Donors Study before the planned interim analysis was performed because of termination of funding. The steering committee did not have knowledge of the clinical outcomes at the time this decision was made.

Of the 918 potential organ donors reported to the organ procurement organizations, 118 patients were randomized and included in the final analysis. Denied consent, legal issues and cardiac arrest were the reason for excluding 355 patients (39%). The remaining 445 patients (42%) were excluded based on standard criteria³ used to identify nonoptimal lungs (**Figure 1**). There were no missing data and no patients were lost to the follow-up.

Baseline characteristics were similar in both groups (**Table 1**). After randomization, ventilation with low tidal volume was lower, and respiratory rate, PEEP, and central venous pressure were higher in protective strategy compared with the conventional strategy. The ratio of PaO₂ to FiO₂ was higher in the protective strategy compared with the conventional strategy at the third and sixth hour of the observation period (**Table 2**).

At study enrollment, the number of patients who met eligibility criteria did not differ between the conventional strategy and the protective strategy. At the end of the 6-hour period, the number of patients meeting lung eligibility criteria decreased in the conventional strategy from 49 (83%) to 32 patients (54%) (difference of 29% [95% CI,

12% to 46%] $P=0.001$). The number of patients meeting lung donor eligibility criteria at the end of the 6-hour period increased slightly in the protective strategy from 51 (86%) to 56 patients (95%) (difference of 9% [95% CI, -2.1% to 19.1%] $P=0.13$). The number of patients in the conventional strategy who met lung eligibility criteria at the end of the six-hour observation period was 32 (54%) compared with 56 (95%) in the protective strategy (difference of 41% [95% CI, 26.5% to 54.8%] $P<0.001$) (**Table 3**). The number of patients in whom lungs were harvested was 16 (27%) in the conventional strategy compared with 32 (54%) in the protective strategy (difference of 29% [95% CI, 10.0% to 44.5%] $P=0.004$).⁷ . Multivariate and regression logistic analysis showed that eligibility at the end of the 6-hour observation period was associated with protective strategy (OR, 25. $P=.001$) and with use of vaso-active drugs at randomization (OR,4.3,; $P=0.02$). The number needed to treat to benefit was 3.0 (95% CI: 1.8- 3.7). Sixteen patients (50%)in the conventional strategy compared with the 24 patients (43%) in the protective strategy (difference of 7 % [95% CI, 0%-29.3%]; $P=.52$) percentage met lung donor eligibility criteria at the end of the six-hour observation period but their lungs were rejected by the surgeon for subsequent transplantation (**Table 3**). We did not find any individual hospital effect when cumulative OR was used as a measure of effect size in a robust logistical regression model.

The number of patients classified as not meeting eligibility criteria by the blinded officer of the organ procurement organization was 27 in the conventional strategy and 3 in the

protective strategy at the end of the eligibility test, which lasted a median of 38 minutes (IQR, 25 to 40 minutes). Patients had a ratio of PaO₂ to FiO₂ of 208 (83) in the conventional strategy and 224 (47) in the protective strategy (difference of proportion, 16; 95% CI, -86 to 116), and a peak airway pressure of 31 (5) cmH₂O in the conventional strategy and 34 (6) cmH₂O in the protective strategy (difference of proportion, 3; 95% CI, -2.9 to 9.1).

The number of patients classified as meeting eligibility criteria by the blinded officer of the organ procurement organization was 32 in the conventional strategy and 56 in the protective strategy at the end of the eligibility test, which lasted a median of 33 minutes (IQR, 20 to 43 minutes). Patients had a ratio of PaO₂ to FiO₂ of 454 (76) in the conventional strategy and 491 (115) in the protective strategy (difference of proportion, 37 CI, -8 to 82) and a peak airway pressure of 26 (4) cmH₂O in the conventional group and 25 (4) cmH₂O in the protective group (difference of proportion, 1; 95% CI -0.5 to 3.2). None of these differences were statistically significant.

The median length of mechanical ventilation from the end of the six-hour observation period to the moment of organ harvest was 6 hours (IQR, 3-16 hours) in the conventional strategy and 4 hours (IQR, 3-18 hours) in the protective strategy. During this period, the ventilator settings selected at randomization were maintained for all patients.

The median intensive care units length of stay for patients who received lungs from donors in the conventional strategy was 12 days (IQR, 1 to 100 days) compared with 8 days (IQR, 2 to 100 days) for patients who received lungs from donors in the protective strategy. The 6-month survival rates was 69% (11/16) for patients who received lungs from donors in the conventional strategy compared with 75% (24/32) for patients who received lungs from donors in the protective strategy (difference of 6%; 95% CI, -22% to 32%). The number of other organs harvested did not differ between the conventional strategy and the protective strategy (hearts: 25 [42%] vs 28 [47%], respectively, difference of 5% [95% CI, -13% to 23%]; livers: 48 [81%] vs 52 [88%], difference of 7% [95% CI, -6.4% to 19.9%]; kidneys: 83 [70%] vs 94 [80%], difference of 10% [95% CI, -1.8% to 20.4%]). Six-month survival did not differ between patients who received other organs from donors in the conventional strategy and the protective strategy (hearts: 70% vs 80%, respectively, difference of 10% [95% CI, -15% to 36%], liver: 94% vs. 94% difference of 0% [95% CI, -0.11% to 0.08%]; kidneys: 95% vs 94%, difference of 1% [95% CI, -0.06% to 0.07%]).

Blood samples were obtained in 20 patients in the conventional strategy and in 17 patients in the protective strategy. Cytokine concentrations at baseline were similar in both groups (**Table 4**). A significant increase over time in IL-6 and tumor necrosis factor receptors was observed in the conventional group ($P < .01$), but not in the protective group; all other measured cytokines did not change over time.

COMMENT

This study demonstrates that a lung protective strategy in potential organ donors resulted in a higher number of eligible donors and harvested lungs compared with a conventional strategy. Of importance, the number of harvested hearts, livers and kidneys did not differ between conventional and protective strategies.

An interim analysis, performed by an independent data and safety monitoring board was planned after data were obtained on the first 100 patients. The steering committee, however, stopped the trial prior to the planned interim analysis because accrual had been slow, and all the funding for the trial had been spent.

Patient No. 100 was randomized on September 30, 2008. The steering committee met to decide whether to ask the data and safety monitoring board to perform the interim analysis as planned by the statistical analysis plan or stop accrual and analyze all included patients as the final data set. Because supplementary funds had been requested, the steering committee was unsure whether the study would proceed. It was decided to maintain the planned interim analysis to avoid the potential loss of α level and continue recruitment until responses from grant agencies were released (expected by Spring 2009). On May 30, 2009, the steering committee was informed that sufficient extra funds to complete the study would not be provided. The steering committee decided: (1) to halt the study and stop randomization, (2) to lock the database with patient No. 118 as the last patient (randomized

on May 26, 2009), and (3) to analyze the data using the criteria that were pre-specified for the final analysis. Of note, if the formal interim analysis had been performed at patient, the data and safety monitoring board members may have stopped the trial at that point because the results crossed the predefined threshold for stopping for efficacy.

Early stopping *for efficacy* of randomized controlled trials may inflate the estimated treatment effect²⁰. We believe this issue may be not relevant in the interpretation of our trial because the decision to stop early was made prior to un-blinding of outcomes by study group and before transmitting the data to the data and safety monitoring board.

In any randomized controlled trial, it is important to ensure that the control group represents a standard of care. We ensured this by basing the control strategy on a consensus conference recommendation that potential lung donors be ventilated with low tidal volumes of 10 to 12 ml/kg of measured body weight using PEEP of 5 cmH₂O⁹. In addition, prior to the current trial, we performed an observational study² that confirmed that the ventilatory strategy used after declaration of brain death was similar to these published recommendations. Despite a review article¹⁰ and an observational study¹¹ suggested that potential lung donors should be ventilated with low tidal volumes of 8 to 10 ml/kg of predicted body weight, guidelines for the management of potential organ donors still recommend ventilation with low tidal volumes of 10 to 15 mL/kg of measured body weight and PEEP of 5 cm H₂O.^{12,13} These discrepancies persist because there has been no high-

grade evidence demonstrating the superiority of any specific strategy for potential lung donors^{10, 21}.

By their nature, the study interventions could not be blinded. To minimize potential bias, we assessed lung viability using well-accepted cutoffs for ratio of PaO₂ to FiO₂ and peak airway pressure obtained during fixed ventilator settings^{3, 14}. These values were communicated to the organ procurement organizations, who then informed the transplant surgeon. The final decision to proceed to lung harvest was made by transplant surgeon after examining the potential donor. Members of the organ procurement organization and surgeons were blinded to study group and not otherwise involved in the study.

All 918 consecutive patients diagnosed as having brain death were assessed for inclusion in the study. However, 39% were excluded for denied consent, legal issues, and cardiac arrest and 42% were excluded based on published criteria that identified non-ideal lungs (**Figure 1**)³. Similarly to other clinical multiorgan donor programs^{1, 3}, our randomized cohort represented 13% of eligible patients. It should be noted that transplant programs participating to the present study did not allow “marginal donors (i.e, patients whose lungs had relative contra-indications such as age, smoking history, contusion, prolonged mechanical ventilation, etc)²²”.

Recent findings suggest that deterioration of lung function may due to mechanisms directly related to brain death^{23, 24}. We hypothesized that ventilatin with low tidal volumes and

higher PEEP levels would prevent the deterioration of lung function associated with brain death²⁵. A number of lines of evidence support this hypothesis that a lung protective strategy will decrease lung injury. First, animal data demonstrate that massive brain injury predisposes the lung to ventilator-induced lung injury²⁶. Second, application of a protective ventilatory strategy in an experimental model improved lung function after lung transplantation²⁷. Third, observational studies demonstrated that ventilation with higher tidal volumes was an independent contributing factor for subsequent development of acute lung injury in patients with acute brain injury⁶. Fourth, protective lung strategies in patients with relatively normal lungs decreased subsequent development of lung injury⁸.

Our results are in accord with these lines of evidence. Prior to randomization, the number of patients who matched eligibility criteria did not differ between the conventional and protective strategy. At the end of the 6-hour period, the number of patients meeting lung eligibility criteria significantly decreased in conventional strategy while they increased slightly in the protective strategy.

Our multi-faceted lung protective intervention addressed 4 factors we hypothesized might affect lung preservation. We used ventilation with low tidal volumes, which improved outcomes in patients with acute lung injury⁷, and decreased the development of acute lung injury⁸. To prevent atelectasis, we used higher levels of PEEP, performed apnea tests using continuous positive airway pressure¹⁷, used a closed system for tracheal suctioning¹⁶ and

used recruitment maneuvers after any disconnection from the ventilator¹⁸. Which of these factors specifically improved respiratory functions is not certain. Ventilation with low tidal volumes of 10 to 12 ml/kg of predicted body weight may overstretch normal lungs in the presence of a markedly decreased pulmonary compliance, which occurs in patients with severe acute lung injury⁷. However, peak pressure and end-inspiratory plateau pressure ranged between 12 and 20 cmH₂O in both groups, values that are substantially lower than the recommended upper limit of 30 cmH₂O²⁸. Under these circumstances, prevention of alveolar overstretch likely does not explain the improvement of lung function observed in the protective strategy. On the other hand, recruitment of collapsed alveoli (obtained by application of recruitment maneuvers), prevention of end-expiratory collapse (obtained by the use of continuous positive airway pressure during the apnea test and of closed suctioning circuit) and maintenances of recruited alveoli (using higher levels of PEEP) may have prevented the pulmonary damage caused by ventilation at low tidal volumes^{5,29}.

In conclusion, our results suggest that the use of a lung protective strategy prevents the decline of pulmonary function consequent to brain death and roughly doubled the number of lungs available for transplantation.

AUTHOR CONTRIBUTIONS

Dr Ranieri had full access the data and takes complete responsibility for the integrity of the data, and the accuracy of data analysis

STUDY CONCEPTION AND DESIGN:LUCIANA MASCIA, ARTHUR S. SLUTSKY, V. MARCO RANIERI

ACQUISITION OF DATA:Luciana Mascia, Daniela Pasero, Arthur S. Slutsky, M. Jose Arguis, Maurizio Berardino, Salvatore Grasso, Marina Munari, Silvia Boifava, Giuseppe Cornara, Francesco Della Corte, Nicoletta Vivaldi, Paolo Malacarne, Paolo Del Gaudio, Sergio Livigni, Elisabeth Zavala, Claudia Filippini, Erica L. Martin, Pier Paolo Donadio, Iliaria Mastromauro, and V. Marco Ranieri

ANALYSIS AND INTERPRETATION OF DATA:Luciana Mascia, Daniela Pasero, Arthur S. Slutsky, Elisabeth Zavala, Claudia Filippini, Erica L. Martin, Iliaria Mastromauro, and V. Marco Ranieri

DRAFTING THE MANUSCRIPT:Luciana Mascia, Arthur S. Slutsky, and V. Marco Ranieri

CRITICAL REVISION OF THE MANUSCRIPT FOR IMPORTANT INTELLECTUAL CONTENT: Daniela Pasero, M. Jose Arguis, Maurizio Berardino, Salvatore Grasso, Marina Munari, Silvia Boifava, Giuseppe Cornara, Francesco Della Corte, Nicoletta Vivaldi, Paolo Malacarne, Paolo Del Gaudio, Sergio Livigni, Elisabeth Zavala, Claudia Filippini, Erica L. Martin, Pier Paolo Donadio, Iliaria Mastromauro

STATISTICAL ANALYSIS: Luciana Mascia, Daniela Pasero, Arthur S. Slutsky, Claudia Filippini, and V. Marco Ranieri

OBTAINING FUNDING:V. Marco Ranieri

ADMINISTRATIVE, TECHNICAL, OR MATERIAL SUPPORT:Luciana Mascia, Daniela Pasero, M. Jose Arguis, Maurizio Berardino, Salvatore Grasso, Marina Munari, Silvia Boifava, Giuseppe Cornara, Francesco Della Corte, Nicoletta Vivaldi, Paolo Malacarne, Paolo Del Gaudio, Sergio Livigni, Elisabeth Zavala, Claudia Filippini, Erica L. Martin, Pier Paolo Donadio, Iliaria Mastromauro

STUDY SUPERVISION:V. Marco Ranieri

FINANCIAL DISCLOSURES:

None reported

FUNDING/SUPPORT

The study was supported by Ministero della Salute, Programma Ricerca Finalizzata # VMR23a/2004-2006, Regione Piemonte, Programma Ricerca Finalizzata # CIPE LM002/2005-2007, Ministero dell'Università, Programmi di Ricerca di Interesse Nazionale # VMRLM98, 2007-2010.

ROLE OF THE SPONSOR

The granting agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

MEMBERS OF THE PROTECTIVE VENTILATORY STRATEGY IN POTENTIAL LUNG DONORS (POPS) STUDY GROUP:

OSPEDALE S. GIOVANNI BATTISTA-MOLINETTE, TORINO, ITALY: (1) *TERAPIA INTENSIVA GENERALE*, Rosario Urbino; (2) *NEURO-RIANIMAZIONE*, Vincenzo Bonicalzi; (3) *RIANIMAZIONE DEA*, Alberto Adduci; (4) **CENTRO TRAUMATOLOGICO ORTOPEDICO, TORINO, ITALY:** *Anestesia e Rianimazione*, Antonio Miletto, Chiara Pescarmona; (5) **OSPEDALE SS ANTONIO E BIAGIO E CESARE ARRIGO, ALESSANDRIA, ITALY:** *Anestesia e Rianimazione*, Giorgio Iotti; (6) **OSPEDALE SANTA CROCE E CARLE, CUNEO, ITALY:** *Anestesia e Rianimazione*, Donatella Isnardi; (7) **OSPEDALE MAGGIORE DELLA CARITÀ, NOVARA, ITALY:** *Anestesia e Rianimazione*, Paolo Navalesi, Laura Cancelliere, Maria Teresa Campailla; (8) **AZIENDA OSPEDALIERA DI PADOVA, ITALY:** *Anestesia e Rianimazione*, Paolo Feltracco, Carlo Ori; (9) **OSPEDALE SANTA CHIARA, PISA, ITALY:** *Anestesia e Rianimazione*, Marzia Lorini; (10) **OSPEDALE CONSORZIALE POLICLINICO, BARI, ITALY:** *Anestesia e Rianimazione*, Tommaso Fiore, Francesco Bruno; (11) **HOSPITAL CLINIC, BARCELONA, SPAIN:** *Department of Anesthesiology*, Joseph Brugada; (12) **OSPEDALE GIOVANNI BOSCO, TORINO, ITALY:** *Anestesia e Rianimazione*, Carlo Alberto Castioni

DATA AND SAFETY MONITORING COMMITTEE:

Chair: Antonio Amoroso, MD (Immunologia Trapianti, Università di Torino, Italy);
Members: Antonio Pesenti, MD (Anestesia e Rianimazione, Ospedale San Gerardo di

Monza, University of Milano-Bicocca, Italy), Franco Merletti, MD Ph.D. (Cancer Epidemiology Unit, CPO Piemonte, CeRMS, Università di Torino, Italy).

STEERING COMMITTEE:

Luciana Mascia, Claudia Filippini, Elisabeth Zavala, Arthur S. Slutsky, V. Marco Ranieri

CONFLICT OF INTEREST

All authors (LUCIANA MASCIA, DANIELA PASERO, ARTHUR S. SLUTSKY, M. JOSE ARGUIS, MAURIZIO BERARDINO, SALVATORE GRASSO, MARINA MUNARI, SILVIA BOIFAVA, GIUSEPPE CORNARA, FRANCESCO DELLA CORTE, NICOLETTA VIVALDI, PAOLO MALACARNE, PAOLO DEL GAUDIO, SERGIO LIVIGNI, ELISABETH ZAVALA, CLAUDIA FILIPPINI, ERICA L. MARTIN, PIER PAOLO DONADIO, ILARIA MASTROMAURO, AND V. MARCO RANIERI) do not have any relevant financial interests and relationships or financial conflicts within the past 5 years and for the foreseeable future relevant to the topic of this study

REFERENCES

1. Ware LB, Wang Y, Fang X, et al. Assessment of lungs rejected for transplantation and implications for donor selection. *Lancet*. Aug 24 2002;360(9333):619-620.
2. Mascia L, Bosma K, Pasero D, et al. Ventilatory and hemodynamic management of potential organ donors: an observational survey. *Crit Care Med*. Feb 2006;34(2):321-327; quiz 328.
3. Van Raemdonck D, Neyrinck A, Verleden GM, et al. Lung donor selection and management. *Proc Am Thorac Soc*. Jan 15 2009;6(1):28-38.
4. Mascia L, Sakr Y, Pasero D, Payen D, Reinhart K, Vincent JL. Extracranial complications in patients with acute brain injury: a post-hoc analysis of the SOAP study. *Intensive Care Med*. Apr 2008;34(4):720-727.
5. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. *JAMA*. Jul 7 1999;282(1):54-61.
6. Mascia L, Zavala E, Bosma K, et al. High tidal volume is associated with the development of acute lung injury after severe brain injury: an international observational study. *Crit Care Med*. Aug 2007;35(8):1815-1820.
7. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med*. May 4 2000;342(18):1301-1308.
8. Determann RM, Royakkers A, Wolthuis EK, et al. Ventilation with lower tidal volumes as compared to conventional tidal volumes for patients without acute lung injury - a preventive randomized controlled trial. *Crit Care*. Jan 7 2010;14(1):R1.
9. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. *Am J Transplant*. Sep 2002;2(8):701-711.
10. Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB. Care of the potential organ donor. *N Engl J Med*. Dec 23 2004;351(26):2730-2739.
11. Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. *Am J Respir Crit Care Med*. Sep 15 2006;174(6):710-716.
12. United Network for Organ Sharing. Critical pathway for the organ donor management . Available at: <http://www.unos.org/resources/pdf/CriticalPathwayPoster.pdf>. *United Network for Organ Sharing*. Accessed November 2010.
13. Canadian Council Donation and Transplantation. Organ donor management: survey of guidelines and eligibility criteria. Available at:

- <http://www.ccdt.ca/english/publications/background-pdfs/Organ-Donor-Guidelines.pdf>.
Canadian Council for Donation and Transplantation. Accessed November 2010.
14. Trulock EP. Lung transplantation. *Am J Respir Crit Care Med*. Mar 1997;155(3):789-818.
 15. Frost AE. Donor criteria and evaluation. *Clin Chest Med*. Jun 1997;18(2):231-237.
 16. Maggiore SM, Lellouche F, Pigeot J, et al. Prevention of endotracheal suctioning-induced alveolar derecruitment in acute lung injury. *Am J Respir Crit Care Med*. May 1 2003;167(9):1215-1224.
 17. Squadrone V, Cocha M, Cerutti E, et al. Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. *JAMA*. Feb 2 2005;293(5):589-595.
 18. Marini JJ. How best to recruit the injured lung? *Crit Care*. 2008;12(3):159.
 19. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. . *Biometrika*. 1977;64:191.
 20. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA*. Mar 24 2010;303(12):1180-1187.
 21. Keegan M.T. WKE, Coursin D.B. An Update on ICU Management of the Potential Organ Donor. *Yearbook of intensive Care and Emergency Medicine*. 2010; Edited by J.-L. Vincent.
 22. Gabbay E, Williams TJ, Griffiths AP, et al. Maximizing the utilization of donor organs offered for lung transplantation. *Am J Respir Crit Care Med*. Jul 1999;160(1):265-271.
 23. Kalsotra A, Zhao J, Anak S, Dash PK, Strobel HW. Brain trauma leads to enhanced lung inflammation and injury: evidence for role of P4504Fs in resolution. *J Cereb Blood Flow Metab*. May 2007;27(5):963-974.
 24. Fisher AJ, Donnelly SC, Hirani N, et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. *Am J Respir Crit Care Med*. Jan 2001;163(1):259-265.
 25. Matuschak GM. Optimizing ventilatory support of the potential organ donor during evolving brain death: Maximizing lung availability for transplantation. *Crit Care Med*. Feb 2006;34(2):548-549.
 26. Lopez-Aguilar J, Villagra A, Bernabe F, et al. Massive brain injury enhances lung damage in an isolated lung model of ventilator-induced lung injury. *Crit Care Med*. May 2005;33(5):1077-1083.
 27. de Perrot M, Imai Y, Volgyesi GA, et al. Effect of ventilator-induced lung injury on the development of reperfusion injury in a rat lung transplant model. *J Thorac Cardiovasc Surg*. Dec 2002;124(6):1137-1144.
 28. Gattinoni L, Caironi P, Cressoni M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. *N Engl J Med*. Apr 27 2006;354(17):1775-1786.

29. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. *J Clin Invest.* Mar 1 1997;99(5):944-952.

FIGURE LEGEND

Figure 1: Assessment of eligibility and inclusion in the Protective Ventilatory Strategy in Potential Lung Donors Study.




TABLE 1: patient characteristics at enrollment

	<i>conventional</i> (N = 59)	<i>protective</i> (N = 59)
Age, mean (SD) y	45(13)	42(13)
Sex		
male gender No. (%)	27 (46)	34 (58)
Primary diagnosis No. (%)		
traumatic brain injury	17 (29)	12 (20)
cerebrovascular accident	37 (63)	45 (76)
other (a)	5 (8)	2 (4)
Duration of mechanical ventilation prior to randomization , median (IQR) h	38 (6-120)	34 (2-120)
Respiratory pattern , mean (SD)		
\dot{V}_E	45(12)	44(11)
tidal volume (mL/kg, predicted body weight)	9.3(1.5)	9.0(1.6)
respiratory rate (breaths/min)	13(3)	13(2)
PEEP (cmH ₂ O)	4.3(2.9)	5.0(2.8)
peak inspiratory pressure (cmH ₂ O)	21(5)	22(4)
plateau pressure (cmH ₂ O)	16(3)	16(4)
minute ventilation (L/min)	7.2(1.9)	7.0(1.7)
ratio of PaO ₂ to FiO ₂	393(144)	400(124)
Arterial blood gases , mean (SD)		
PaO ₂ (mmHg)	171(112)	173(74)
SaO ₂ (%)	98(2)	99(1)
PaCO ₂ (mmHg)	36(5)	36(6)
arterial pH	7.44(0.07)	7.43(0.07)
Hemodynamic variables , mean (SD)		
mean arterial pressure (mmHg)	84(16)	83(16)
central venous pressure (mmHg)	6.4(2.9)	7.5 (2.8)
sedative drugs, No. (%)	47 (80)	47 (80)
Concomitant treatment (b)		
dopamine, median (IQR) (μg/kg/min)	7.5 [1-15]	6.5 [0.9-17]
norepinephrine, median (IQR) (μg/kg/min)	0.13 [0.02-0.25]	0.16 [0.02-0.30]
dexamethasone, No (%)	10(17)	12(20)
levothyronine or thyroxine, No (%)	9(15)	8(14)
octreotide, No (%)	2(3)	1(2)

Abbreviations: FiO₂ : fraction of inspired Oxygen ; IQR: Interquartile range; PEEP : positive end expiratory pressure; SaO₂= arterial oxygen saturation

(a) Such as for ischemic stroke

(b) Eighteen patients in each group received dopamine and norepinephrine in combination.

TABLE 2: ventilatory and hemodynamic variables during the 6 hours of treatment

	1 st hour		3 rd hour		6 th hour	
	<i>conventional</i> (n = 59)	<i>protective</i> (n = 59)	<i>conventional</i> (n = 59)	<i>protective</i> (n = 59)	<i>conventional</i> (n = 59)	<i>protective</i> (n = 59)
ventilatory variables, mean (SD)						
FiO ₂	47(17)	42(7)	48(18)	44(12)	50(19)	44(11)
tidal volume (ml/kg, predicted body weight)	10.1(1.6)	7.9(1.1)a	10.1(1.6)	7.8(1.0)	10.1(1.7)	7.8(1.0)
respiratory rate (breaths/min)	11(2)	13(3)a	11(2)	14(3)	11(2)	14(3)
PEEP (cm of water)	4.2(1.6)	8.7(1.4)a	4.4(1.5)	9.0(1.4)	4.3(1.6)	9.2(1.8)
peak inspiratory pressure (cm of water)	22(5)	23(5)	23(5)	23(4)	22(5)	23(5)
plateau pressure (cm of water)	16(4)	17(4)	17(4)	17(3)	17(4)	18(4)
minute ventilation (liters/min)	6.9(1.5)	6.5(1.7)	6.8(1.8)	6.6(1.8)	6.8(1.7)	6.7(1.9)
ratio of PaO ₂ to FiO ₂	360(120)	402(118)	342(126)	402(129)b	332(170)	396(107)b
blood gas analysis, mean (SD)						
PaO ₂ (mmHg)	164(72)	166(54)	165(92)	176(72)	156(84)	169(49)
PaCO ₂ (mmHg)	39(7)	39(6)	41(8)	42(5)	42(10)	41(5)
pH	7.42(0.06)	7.41(0.07)	7.41(0.07)	7.39(0.07)	7.40(0.07)	7.39(0.09)
hemodynamic variables						
mean arterial pressure, mean (SD) (mmHg)	83(14)	84(15)	84(15)	83(14)	82(16)	86(17)
central venous pressure, mean (SD) (mmHg)	7.0(2.7)	8.3(2.9)b	6.5(2.8)	8.2(3.2)	7.0(2.8)	8.5(2.8)
sedative drugs, No (%)	49 (83)	47 (80)	49 (83)	46 (78)	50 (85)	44 (75)

Abbreviations: FiO₂ : fraction of inspired Oxygen ; IQR: Interquartile range; PEEP : positive end expiratory pressure; SaO₂= arterial oxygen saturation
 (a) P < 0.0001 for comparison with *conventional* ventilatory strategy;
 (b) P < 0.05 for comparison with *conventional* ventilatory strategy using mixed model linear regression for repeated measure.

Table 3. End-points in the conventional and protective groups.

	<i>conventional</i> (n = 59)	<i>protective</i> (n = 59)	<i>Difference of proportion</i> (95% CI)
Met lung donor eligibility criteria			
AT STUDY INCLUSION			
No. (% of randomized patients)	49 (83)	51 (86)	3 (-4.0; 24.4)
6 HOURS AFTER RANDOMIZATION			
No. (% of randomized patients)	32 (54) ^a	56 (95) ^b	41 (26.5; 54.8)
Lungs harvested			
Yes (% of randomized patients)	16 (27)	32 (54) ^c	27 (10.0; 44.5)
No	32 (50) ^d	4/56(43) ^d	7(0 to 29.3)
Reasons lungs not harvested			
(d) (% of patients meeting lung donor eligibility criteria at the end of the 6-hour observation period)			
TOTAL	16 (50)	24 (43)	7 (0; 29.3)
FUNCTIONAL REASONS,	4 (25)	7 (29)	
INFECTIOUS REASONS,	3 (19)	4 (17)	
INSPECTION REASONS	3 (19)	5 (21)	
DONOR-RECIPIENT INCOMPATIBILITY	4 (25)	5 (21)	
LOGISTICAL REASONS	2 (12)	3 (12)	

Abbreviation: CI, confidence interval.

(a) $P = .001$ using the McNemar test at study inclusion compared with 6 hours after randomization.

(b) $P = .001$ for comparison with conventional ventilatory strategy using the Fisher exact test.

(c) $P = .004$ for comparison with conventional ventilatory strategy using the χ^2 test.

(d) Values expressed as number/total (percentage).

Table 4. Cytokines in the conventional and protective ventilatory strategies.

	<i>conventional</i>		<i>protective</i>	
	<i>Baseline (n=20)</i>	<i>6th hour (n=20)</i>	<i>Baseline (n=17)</i>	<i>6th hour (n=17)</i>
IL-1 beta, pg/ml	0.24 [1.28-0.01]	0.52 [2.18- 0.01]	0.35 [0.84-0.01]	0.28 [0.73-0-01]
Il-1 RA pg/ml	129 [686-97]	158 [562-84]	133 [672-71]	48 [539-7]
IL-8, pg/ml	17 [72-0.49]	18 [117-8]	16 [77-0.01]	14 [56-0.01]
TNF-alpha, pg/ml	1.40 [22-0.10]	1.0 [15.0-0.10]	1.0 [15-0.01]	1.0 [14-0.01]
IL-6, pg/ml	407 [3138-31]	1025 [4716-282]*	158 [3622-13]	259 [2620-21]
TNF receptor I, pg/ml	2571 [5426-1083]	4105 [63351-3001] *	2381 [4266-923]	2625 [5185-1368]
TNF receptor II, pg/ml	5245 [10632-2011]	8889 [19323-6064] *	4359 [9673-2480]	5187 [9612-2392]

Data are presented as median [interquartile range] pg/m L. *: P < 0.05 for comparison with baseline using paired t-test on log₁₀ transformed values.